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Feasibility Trial in Residential Aged Care Facilities 3 
 4 
Introduction   5 
Prescribing medicines is practiced routinely and is often driven by test results, symptoms or a confirmed 6 
disease diagnosis [1], with some prescribers considering continuing prescribed medicines as the safer 7 
course of action [2]. However, older adults with co-morbidities may benefit to a lesser degree from 8 
medicines due to competing risks of negative health outcomes, including medication-related harms and 9 
death before benefits can be accrued [3].   10 
Deprescribing, the supervised withdrawal of unnecessary medications to minimize polypharmacy [4] is 11 
linked to potential health gains including improvements in cognition [5], reduction in falls and hip 12 
fractures [6, 7], improved medication adherence [8] and other positive health outcomes [5-7, 9]. However, 13 
this is not perceived as an easy process and the challenges of reviewing medication are many and 14 
transverse multiple healthcare processes [10].   15 
With ever-increasing demands on the healthcare system by an ageing population worldwide [11, 12], it is 16 
important to address the challenges of implementing deprescribing in a safe and feasible manner. In New 17 
Zealand, these challenges include time constraints, fear of consequences and lack of accessibility to 18 
guidelines and processes that empower physicians to deprescribe medication [10, 13]. The best approach to 19 
implementing deprescribing, addressing major deprescribing barriers, is not yet clearly understood [14]. 20 
This study examines the feasibility of deprescribing anticholinergics and sedatives in older people in 21 
residential care facilities using a pharmacist-led intervention.   22 
 23 
These medicines are commonly prescribed [15] and are associated with both cognitive and physical 24 
functioning impairment [16]. Several tools can be used to measure the anticholinergic and sedative burden 25 
[17]. We chose the Drug Burden Index (DBI) as this has been validated in several older populations 26 
worldwide [18] and studies have shown a correlation between increasing DBI and worse patient outcomes, 27 
including mortality, cognition, frailty and falls [18]. Each additional unit of DBI exposure has a negative 28 
effect on older people’s physical function similar to that of three additional comorbidities [19]. Therefore, 29 
the DBI provides a useful tool to help inform improved prescribing patterns. 30 
Aim of the study  31 
Our overarching aim was to test the feasibility of a collaborative pharmacist-led medication review with 32 
General Practitioners (GPs). The review utilised a patient-centred approach to implement deprescribing 33 
recommendations based on peer-reviewed deprescribing guidelines. We hypothesise that DBI could be 34 
reduced in residential aged care facilities (RACFs) utilising this intervention.  35 
Ethics Approval  36 
Ethics approval was obtained from the Health and Disability Ethics Committee (16/NTA/61).  37 
Methods 38 
 39 
This trial’s methods are outlined in a published protocol [20]. The trial was registered in the Australasian 40 
Clinical Trials Registry (ACTRN12616000721404). The Template for Intervention Description and 41 
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Replication (TIDieR) checklist was used when designing the study (Supplementary Table 1). The study 42 
is diagrammatically represented using CONSORT Reporting Guidelines in Supplementary Figure 1 [21].   43 
 44 
Study Design  45 
 46 
A single group (pre- and post- comparison) feasibility study was carried out in people aged 65 years and 47 
older living in a residential care setting. Figure 1 provides an overview of the intervention. Participants 48 
were recruited from three RACFs in New Zealand.  49 
 50 
Power and sample size 51 
To detect a clinically significant difference in the primary outcome (reduction in DBI total score of 0.5 or 52 
more) with 80% power and alpha of 0.05, the total sample size required was 72 participants [20]. This 53 
effect size is derived from a study conducted in Australian RACFs that aimed at decreasing the DBI load 54 
[22]. Power calculations were generated using Stata 13.1 (Copyright 1985-2013 StataCorp LP).  55 
 56 
Inclusion and Exclusion Criteria   57 
Participants who are aged ≥ 65 years who are prescribed at least one anticholinergic or sedative medicine 58 
(i.e. DBI≥0.5) were included. The target medicine list was adapted from Hilmer et al. [23]. Those who 59 
were expected to have a limited life expectancy, receiving palliative care or those admitted for hospice care 60 
were excluded.  61 
 62 
Recruitment and consent 63 
The RACF’s e-prescribing program was screened for residents who fulfilled the inclusion criteria. Of 64 
these, nurse(s) determined residents who were able to provide consent. The pharmacist provided these 65 
residents with a participant information sheet and consent form. For residents with cognitive impairment; 66 
the pharmacist gained consent via their enduring power of attorney (EpoA). Recruitment continued for 4 67 
months.  68 
Intervention  69 
A collaborative pharmacist-led medication review with GPs was employed, as this model has been shown 70 
to improve the success of deprescribing [24].  71 
Step 1: Medical history  72 
 73 
The InterRAI-Long Term Care Facility (LTCF) is a comprehensive assessment database system, utilised in 74 
RACFs internationally and in New Zealand to standardise the evaluation of older people’s complex care 75 
needs. It is used routinely to collect data regarding patients’ medical and functional status [25]. We used 76 
this along with clinical notes, to collect participants’ data. The reliability of InterRAI-LTCF has been 77 
tested and shown to meet the standard cut-offs for acceptable reliability [26].  78 
Step 2: Initial consultation  79 
After completing an initial consultation, potential medicine(s) that could be deprescribed were discussed 80 
and any patient concerns were noted. For participants with diminished cognition, the pharmacist invited a 81 
nurse and/or the EpoA to help facilitate communication. When a response from the participant was not 82 
possible, the test was recorded as ‘not assessed’ and the information was gathered from clinical notes.  83 
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 86 
Step 3: Deprescribing medication review  87 
The deprescribing medication review utilised peer-reviewed deprescribing guidelines developed as part of 88 
the principal investigator’s doctoral studies [20]. When these target medicines are reduced/discontinued, 89 
adverse drug withdrawal effects (ADWEs) may develop including increased agitation, pain, confusion, or 90 
disturbed sleep patterns [27]. Therefore, it is important to slowly taper these medicine(s) whilst monitoring 91 
the participant. Medicine(s) that can be deprescribed were discussed with each participant and their 92 
consent to deprescribe was sought. When participants disagreed, these recommendations were removed 93 
from the review ensuring this is a patient-centred approach. Similarly, for participants with diminished 94 
cognition, approval for deprescribing recommendations was sought from their EpoA before putting 95 
forward these recommendations to the GP. The GP reviewed, endorsed, adjusted or rejected the 96 
recommendations. Any reasons for rejection were recorded.  97 
Step 4: Medication management plan  98 
We developed a medication management plan (MMP) that included individualised tapering and monitoring 99 
recommendations for the participant, GP and residential care staff.  The MMP listed the medicines to be 100 
deprescribed, the recommended order of deprescribing, specific tapering guidance, anticipated ADWEs, 101 
monitoring and appropriate management options for withdrawal effects. The participant and/or their 102 
relative/representative were provided with a copy of the plan. The GP then initiated deprescribing and all 103 
other aspects of follow up care.  104 
Step 5: Monitoring and follow-up  105 
After the cessation/dose reduction of the first target medicine, participants were monitored twice weekly 106 
by the pharmacist for ADWEs. If none were reported, dose reduction continued until the medicine was 107 
stopped. The participant continued to be reviewed twice weekly for a further two weeks, and if symptoms 108 
were stable, the dose of the next target medication was reduced until it was ceased. This process was 109 
repeated until all target medicines were withdrawn. The participant was monitored by the pharmacist on a 110 
weekly basis for two more visits and, if stable, no additional visits were conducted. Monitoring also took 111 
place independently by nursing staff. GPs were notified if their resident developed an ADWE to facilitate a 112 
GP visit and/or re-prescribing of medicine(s) as appropriate.  113 
Data Collection and Analysis:  114 
During the initial consultation, frailty was assessed using the Edmonton Frailty Scale [28], depression was 115 
assessed using the Geriatric Depression Scale (GDS)  [29], side effects attributed by target medicines were 116 
assessed using UKU- Side Effect Rating Scale (UKU-SERS) score [30] and quality of life (QoL) was 117 
assessed using EQ-5D-3L [31]. Covariates were collected at baseline (T0), after three months (T1) and 118 
after six months (T2) as detailed in the study protocol [20] and supplementary Table 2. Data was be 119 
stored in a password-protected Excel spreadsheet.  120 
 121 
Primary Outcome: The change in the participant’s DBI three and six months after the deprescribing 122 
intervention had been implemented. PRN ‘as required’ DBI medicines that had been administered more 123 
than once in the past three months were included in the total DBI score. A separate DBI PRN was also 124 
calculated.   125 
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Secondary Outcomes: An in-depth description of these outcomes is included in the study protocol [20] and 126 
in Supplementary Table 3.  127 
 128 
 129 
Statistical Methods  130 
Data were analysed on an intention-to-treat basis. R was used for statistical analyses [32]. The primary 131 
outcome of change in the DBI at three and six months was assessed with a Wilcox-signed Rank Test 132 
(WSR). Depending on the distribution of secondary outcome data, either a paired t-test or WSR were used 133 
for analysis at three and six months. Fisher’s exact test was used to analyse the uptake of deprescribing 134 
recommendations.  135 
Results  136 
In total, 46 of 65 potentially eligible participants consented and were enrolled (Figure 2). Our study 137 
attrition rate was 8.7%, with four residents passing away for reasons unrelated to the deprescribing 138 
intervention.  Participant demographics are summarised in Table 1. Almost half of participants had a high 139 
falls risk (41%) and the majority (93%) had polypharmacy, which was defined as the prescription of five or 140 
more medicines [33].  141 
 142 
In total, the pharmacist suggested 45 deprescribing recommendations among 46 residents. Of these, 82% 143 
were agreed upon by the residents’ GP and 96% were agreed upon by the resident or the resident’s 144 
relatives/family (Table 2). In total, 33 recommendations (72%) were implemented (p=0.01; Fisher’s exact 145 
test); and the medicines were re-prescribed by the GP in only five instances (15.2%). Deprescribing 146 
processed could not be completed in 13 residents (28.2%) due to mood changes, increased pain levels or 147 
overall health deterioration.  148 
 149 
Table 3 illustrates the analysis of primary and secondary outcomes three months after deprescribing and 150 
Table 4 illustrates the analysis six months after deprescribing. Participant’s overall DBI and DBI PRN 151 
were significantly less three months after deprescribing. Six months after deprescribing (Table 4), the DBI 152 
remained statistically significantly decreased by a median of 0.34. Six months after deprescribing, total 153 
regular medicines were reduced statistically, by a mean difference of 2.13 medicines per patient, among 154 
patients were deprescribing was initiated. However, the use of PRN medicines remained the same. Falls 155 
risk was determined using an in-house falls risk assessment tool utilised by most RACFs in New Zealand 156 
and 41% of residents had a high falls risk at the time of recruitment. This remained the same six months 157 
after deprescribing. Fall rate defined as the number of falls in the past 90 days was determined by interRAI 158 
and showed a statistically significant reduction.  Frailty, assessed using the Edmonton Frailty Scale, also 159 
showed a significant decrease;  the mean difference was 1.35 (p<0.05, 95%, CI: -2.22; -0.48). QoL 160 
assessed using EQ-5D-3L was not significantly different six months after deprescribing.  161 
 162 
Six months after deprescribing, total regular medicines were reduced statistically, by a mean difference of 163 
2.13. However, the use of PRN medicines remained the same. Fall rate was determined using falls data 164 
recorded in interRAI, where the number of falls that occurred in the past 90 days was noted. Falls risk was 165 
determined using an in-house falls risk assessment tool utilised by most RACFs in New Zealand. Forty-one 166 
percent of residents had a high falls risk at the time of recruitment. This remained the same six months 167 
after deprescribing. On the other hand, the participants’ number of falls statistically significantly dropped. 168 
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Frailty assessed by the Edmonton Frailty Scale also dropped by a mean difference of 1.35 (p<0.05, 95%, 169 
CI: -2.22; -0.48). QoL assessed by EQ-5D-3L did not improve six months after deprescribing.  170 
 171 
Participants reported significantly less adverse effects of psychotropic medication at 3 and 6 months after 172 
deprescribing than at the time of recruitment. Psychiatric, neurological, autonomic and other adverse 173 
effects dropped significantly 3 and 6 months after deprescribing. Psychiatric adverse effects decreased by a 174 
mean difference of 1.8 (p<0.05; 95%, CI: -2.6; -1.0) 3 months after deprescribing, and by a mean 175 
difference of 2.24 (p<0.05; 95%, CI: -3.63; -1.12) after 6 months of deprescribing.  176 
 177 
Potential adverse drug reactions (ADRs) had decreased by a mean difference of 2.8 three months after 178 
deprescribing (p<0.05; 95%, CI: -4.00; -1.64) and by 4.24 after six months (p<0.05; 95%, CI: -5.66; -2.83). 179 
We found no change in cognition three or six months after deprescribing. However, participants’ levels of 180 
depression scored using the GDS significantly improved (Median difference: -2; p<0.05). 181 
 182 
Discussion  183 
 184 
This feasibility study implemented a targeted systematic intervention of deprescribing anticholinergic and 185 
sedative medicines using a five-step patient-centred approach. We aimed to explore the feasibility of a 186 
pharmacist-led deprescribing intervention that can address some of the major barriers associated with 187 
deprescribing, and our results support the feasibility of such an approach [20].  188 
The findings from this feasibility trial support existing research that shows that despite the challenges, 189 
rationalising the use of medicines in older people through deprescribing is feasible and may realise 190 
potential benefit [27]. Our results are consistent with other studies that illustrate that deprescribing 191 
contributes to an overall reduction in pill burden [5, 9, 27].  192 
 193 
Most eligible patients or their EpoAs, consented to participation and overall, 45 recommendations were 194 
suggested to the residents’ GPs. Eighty-two percent of these were agreed upon by the residents’ GP; 72% 195 
of them were implemented. Despite previous studies reporting residents’ unwillingness to discontinue 196 
medicines, we found that the majority of residents and/or their representatives (96%) agreed with the 197 
deprescribing recommendations. This finding is echoed in another cross-sectional survey, which showed 198 
that most residents (78.9%) reported a desire to stop taking one or more of their medicines [34].  199 
Though not powered to detect a significant difference, this study sheds light on the effect that 200 
deprescribing has on participants’ DBI scores and relevant patient health outcomes. The statistically 201 
significant reduction in DBI scores by 0.34 may support  clinical relevance in a larger study; as although in 202 
our feasibility study this represents a small decrease, studies have shown an association between increasing 203 
DBI and impaired functioning [23, 33, 35, 36].  204 
 205 
Participants reported lower depression and frailty scores six months after deprescribing. Cognition, 206 
however, did not improve after deprescribing, nor did participants’ QoL scores. Our study was not 207 
powered to detect these differences and we can only speculate that six months is not long enough to 208 
observe such differences, especially in older patients who may suffer from cognitive impairment. 209 
However, the lack of QoL deterioration over the period of the study could be a positive finding attributed 210 
to deprescribing that ought to be explored in further studies [14].   211 
 212 
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Psychotropic-related ADEs were reduced six months after the deprescribing intervention. This finding 213 
supports existing evidence that the withdrawal of specific medication classes, including benzodiazepines, 214 
leads to the reduction of ADRs [15]. There were no adverse events noted as a result of deprescribing. 215 
Approximately, fifteen percent of the participants had to have one or more of their deprescribed medicines 216 
re-prescribed. Despite this, the overall number of medicines prescribed was reduced significantly. This 217 
illustrates that deprescribing was well tolerated, supporting previous research that has shown that frail 218 
older people’s medication burden can be reduced without any detrimental effects to their health [5, 9].  219 
 220 
 221 
 222 
Strength and Limitations  223 
The study design meant that the participants and outcome assessment were not blinded. However, several 224 
outcomes were objective measures, such as the DBI, hence mitigating the risk of assessment. ADWEs 225 
were assessed subjectively by the pharmacist and the residential care staff; introducing possibility of bias. 226 
The potential that a placebo effect may underpin some changes seen is another limitation that is inherent to 227 
pre-post intervention studies. However, this does not affect the study’s primary outcome; the change in 228 
DBI scores. Time-period effects cannot be ruled out, as controls were not included in the study design.  229 
 230 
No restrictions were put in place to prevent medicines being re-prescribed. This pragmatic approach 231 
mimics real-life clinical scenarios where medicines are often re-prescribed after being stopped for several, 232 
often appropriate, reasons. Despite having a relatively high recruitment rate of 71%, we were unable to 233 
recruit the calculated sample size (n=72) due to strict eligibility criteria. We had anticipated this, as other 234 
deprescribing studies had shown recruitment could be challenging mainly due to the fear associated with 235 
deprescribing medicines [37]. Although our study showed improvement in the majority of outcome 236 
measures, six months is not an adequate term to observe changes related to cognitive function.  237 
 238 
We found that some participants perceived deprescribing as ‘going against’ their GPs’ initial decision of 239 
prescribing the target medicine(s) in question. Re-assuring them that recommendations would be discussed 240 
and finalised with and by their GP appeared to support participation in decisions regarding their medicines 241 
[38]. Other challenges we encountered included time constraints faced by GPs [39]. Scheduling face-to-242 
face GP appointments for the pharmacist to discuss recommendations was challenging. However, once 243 
scheduled, thirty-minute visits were adequate to review recommendations and implement any necessary 244 
medicine changes.  245 
Engaging a patient-centred approach was crucial, as the aim of deprescribing is to address patients’ health 246 
concerns [1] and respect their preferences. This has been shown to significantly improve medication 247 
adherence [8]. Utilising a clinical pharmacist to perform the reviews; helped address time constraints faced 248 
by GPs [40]. Assuring GPs that residents are receiving adequate monitoring may also have increased the 249 
confidence of GPs by diminishing concerns around potentially harmful effects often associated with 250 
deprescribing [40].  251 
 252 
Conclusion  253 
This study provides important data indicating the feasibility and benefits of reducing anticholinergic and 254 
sedative medication in frail older people. The approach used resulted in high uptake of deprescribing 255 
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recommendations by both residents and GPs. At six months, deprescribing showed signals of significant 256 
benefits across a range of important health outcomes including mood, frailty, and falls and resulted in a 257 
smaller number of reported adverse effects. Implementing deprescribing utilising this patient-centred 258 
approach appears to be safe and feasible and can yield potential health benefits in older people.   259 
 260 
Funding statement 261 
This study was carried out as part of NA’s doctoral studies at the University of Otago, School of Pharmacy 262 
and is funded by the Lotteries Health Research (LHR). No other funding was received for this study. 263 
Conflicts of interest 264 
The author(s) declare no competing interests and are responsible for this report’s content.  265 
 266 
Acknowledgments  267 
The authors thank LHR for funding the first author’s doctoral studies and the co-operation of the 268 
residential care provider who agreed to take part in the study. 269 
 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 288 
DEFEAT-polypharmacy  
 8 
 289 
 290 
 291 
 292 
 293 
 294 
Table 1: Social and Demographic Data  295 
Characteristic  n % 
Sex    
Female 34 74 
Male 12 26 
Ethnicity    
Caucasian  45 98 
Asian 1 2 
Falls risk    
Low 14 30 
Moderate  13 28 
High 19 41 
Polypharmacy    
≥5 medicines 43 93 
<5 medicines 3 07 
Charlson Comorbidity Index (CCI)    
1 2 4 
2 6 13 
3 18 39 
4 13 28 
5 5 11 
6 2 4 
Body Mass Index (BMI)    
Underweight: 18.5-24.9  19 41 
Normal: 25-29.9 18 39 
Overweight: ≥30 9 20 
Activities of Daily Living (ADL)   
0: Independent  16 35 
1: Supervision  8 17 
2: Limited  8 17 
3: Extensive  9 2 
4: Maximal  2 4 
5: Dependent  3 7 
Pain Scale   
0: No pain  19 41 
1: Less than daily pain 25 54 
2: Daily pain but not severe  5 11 
ABS*   
0: No instances of aggressive 
behaviour  
36 78 
1 3 7 
2 3 7 
3 2 4 
4 1 2 
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 296 
 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
ABS*: Aggressive Behaviour Scale. Scale scores range from 0-12 with higher scores indicative of greater frequency and diversity of aggressive behaviour. 330 
CHESS: Changes in Health, End-Stage Disease, Signs, and Symptoms Scale. EQ-VAS:  EQ Visual Analogue Scale.  331 
8 1 2 
CHESS*    
0=No health instability  22 48 
1=Minimal health instability 12 26 
2=Low health instability 6 13 
3=Moderate health instability 3 7 
4=High health instability 3 7 
5=Very high health instability 0 0 
 EQ-VAS*   
Report < 50  17 37 
Reports 50 7 15 
Report > 50  22 48 
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Table 2: Deprescribing recommendations  
Resident 
number  
Number of  
recommendation
s put forward to 
GP 
Number of 
recommendation 
agreed by the 
GP 
Number of 
recommendations 
agreed by 
resident/resident's 
family Deprescribing recommendations put forward to GP with clinical reasoning 
 
 
 
 
Summary  Represcribed Deprescribed  
1 2 2 2 
Loratadine: Resident prescribed promethazine as well as loratadine for eczema. Resident 
however reported that promethazine is more effective at relieving their symptoms. Therefore, 
the suggestion was made to the GP* to discontinue loratadine and monitor the control of 
itching symptoms with promethazine alone. GP* agreed with this suggestion.  
 
Tramadol: Resident reported feeling sleepy during the day and drifting off to sleep regularly. 
Reducing her tramadol dose from 100mg SR* BD* to 50mg SR* mane* or BD* could help to 
increase energy levels during the day, whilst still providing long-acting pain relief.  
Loratadine 
(discontinued) 
 
 
 
Tramadol 
(reduced) 
N Y 
2 2 1 2 
Nortriptyline: Resident suffers from pain that had been well managed with paracetamol. A 
reduced dose of nortriptyline was therefore thought to be beneficial to improve the resident’s 
energy levels during the day. GP* agreed with this suggestion.  
 
Risperidone: Has a past history of paranoid schizophrenia; so continuing risperidone is 
necessary. However, resident’s mood seemed to be well controlled and stable over the past 
five years; suggested to the GP* to trial reducing the dose from 1mg to 0.5mg. GP had 
attempted to reduce risperidone dose in the past and this resulted in relapse of symptoms. 
Therefore risperidone was continued.  
Nortriptyline 
(reduced)  
 
 
Risperidone  
(continued)  
N Y 
3 1 1 1 
Quetiapine: Low dose quetiapine prescribed for aggressive behaviour exhibited by resident 
upon admission into the residential care facility approximately a year and a half prior to 
assessment date. As resident did not exhibit any recent acts of aggressive behaviour, the 
suggestion was put forward to deprescribe quetiapine; whilst continue to prescribe this ‘as 
required’. After three months, this change was well tolerated with no relapse of symptoms and 
the quetiapine did not need to be administered ‘as required’. Therefore, it was successfully 
discontinued.  
Quetiapine 
(discontinued)  
N Y 
4 1 1 1 
Carbamazepine: A dose reduction from 200mg BD* to 100mg BD* was suggested as 
resident’s epileptic symptoms have been well controlled with no attacks during the entirety of 
the resident being admitted into the residential care facility (approximately 5 years). The 
resident had also expressed that they do not believe they require to continue taking this 
medication. Discussed with GP who agreed and reduced the dose of carbamazepine. Resident 
passed away on the 24/09/16 due to chest infection  
Carbamazepine 
(discontinued) 
N Y 
5 4 2 2 
Nortriptyline: Resident prescribed several medicines for neuropathic pain caused by ulcers 
secondary to Type 2 Diabetes Mellitus. Resident reported feeling drowsy and loss of 
concentration during the day. This affected their ability to partake in social activities. 
Suggestion was made to GP* to reduce nortriptyline dose from 50mg to 25mg. GP* agreed. 
After three months, the dose reduction was well tolerated and GP* decided to discontinue the 
use of nortriptyline.  
 
Zopiclone: Resident had been prescribed this long-term for sleep aid. However, resident still 
experienced difficulty falling asleep and staying asleep. Attempting to reduce the resident’s 
high drug burden index by reducing/discontinuing nortriptyline that caused sleepiness during 
the day; was thought to provide the opportunity for better quality sleep at night therefore 
Nortriptyline 
(discontinued) 
 
 
 
 
Zopiclone  
(discontinued) 
 
N Y 
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reducing the reliance on continuing this medication. Resident refused the zopiclone tablet 
three months after discontinuing nortriptyline, as they felt they no longer needed it and slept 
well without it. The GP* therefore discontinued zopiclone.  
 
Other medicines that were suggested for reduction were tramadol and gabapentin after 
nortriptyline and zopiclone were successfully deprescribed. However, GP did not want to risk 
reducing these medicines as resident’s pain might not be well managed at lower doses.  
6 4 1 4 
Quetiapine: Indication for prescribed low dose quetiapine was not documented and unclear. 
Therefore, suggestion was made to reduce quetiapine with the aim of completely discontinuing 
this. GP* agreed. However, resident passed away on 14/04/17 before further tapering of the 
dose was possible.  
 
Resident had a high drug burden index. Other deprescribing recommendations put forward 
included a step wise approach to reduce the dose of zopiclone, amitriptyline and lorazepam. 
GP* felt comfortable with reducing quetiapine and was hesitant to reduce other medicines as 
the resident had been prescribed them for a long time.  
Quetiapine 
(reduced)  
N Y 
7 1 0 1 
Lamotrigine: At the time of assessment, it seemed appropriate to trial the reduction of 
lamotrigine as the resident had not suffered from a recent attack. However, shortly after this 
the patient had a seizure, and due to her moods being chronically low, the decision to continue 
lamotrigine was made.   
Lamotrigine 
(continued) 
N N 
8 1 1 1 
Gabapentin: Prescribed many sedative medicines for pain control, including opioids. 
Discussed with GP* possibility of reducing gabapentin dose and they agreed with this 
suggestion.  
Gabapentin 
(reduced)  
N Y 
9 1 1 1 
Risperidone: Prescribed two antipsychotics for schizophrenia and behaviours associated with 
personality disorder. Discussed with GP* the possibility of simplifying the regimen and they 
decided that stopping risperidone; whilst continuing olanzapine would be appropriate.  
Risperidone  
(discontinued)  
N Y 
10 2 2 2 
Morphine: Pain managed well with paracetamol and other medicines. Suggestion made to stop 
morphine which was taken up by the GP*. 
 
Citalopram: Resident has been in good moods for the past six months and does not suffer from 
chronic depression or low moods on a constant basis. Suggestion to trial discontinuing this 
was made and the GP* agreed.   
 
Resident passed away on 02/05/2017 due to general deterioration in health. 
Morphine 
(discontinued) 
 
Citalopram 
(discontinued)  
N Y 
11 1 0 1 
Tramadol: Suggested to the GP* to reduce tramadol dose as patient had previously been 
prescribed this during an acute stage of pain after injuring her foot. However, GP* expressed 
that he did not want to taper down tramadol at this stage, as he was stopping other 
cardiovascular medicines at the time.  
Tramadol  
(continued) 
N N 
12 1 1 1 
Prescribed zopiclone for many years and resident reported they felt dependent on it and was 
unsure that they require it. Relayed the resident’s interest to try and reduce or stop the use of 
it. GP* agreed to and the dose was reduced from 7.5mg to 3.75mg. Patient tolerated this well. 
At the three months assessment, the resident did not feel comfortable with completely 
discontinuing zopiclone and continued taking half a tablet.  
Quetiapine 
(reduced)  
N Y 
13 1 1 1 
Quetiapine: Prescribed 75mg BD*, to control hallucinations. Resident has not suffered from 
hallucinations for a considerable time and was exhibiting signs of sedation during the day and 
loss of concentration. Suggested reducing the dose to 50mg BD* and prescribing 12.5mg ‘as 
required’. GP* agreed with this suggestion. Resident tolerated the reduced dose well and did 
not require additional administration of ‘as required’ quetiapine  
Quetiapine 
(reduced)  
N Y 
14 1 1 1 
Escitalopram: Indication not clearly documented and resident appears to be overall well with 
consistent good moods. Suggestion to reduce escitalopram dose with the aim of 
discontinuation was made and GP* agreed to reduce it. GP* did not feel comfortable 
Escitalopram 
(reduced)  
N Y 
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discontinuing this completely at the time however, as the resident suffered from other pain 
related issues. 
15 2 2 2 
Amitriptyline: Prescribed 10mg amitriptyline along with several other sedative and 
anticholinergic medicines. Indication for amitriptyline was unclear and not documented. 
Resident thought it might have been prescribed for insomnia; albeit she did not consider this to 
be effective. Therefore, suggested to GP* to discontinue. GP* agreed with this suggestion.   
 
Codeine: Prescribed 60mg TDS* with no clear indication. At the time of assessment, resident 
reported experiencing dizzy spells, feeling light headed and falling out of her wheelchair a 
week prior to the assessment. As the resident is a one-leg amputee, frail and has a low BMI, 
slow tapering of codeine was suggested to the GP* to reduce the resident’s drug burden index.  
 
GP* agreed to both suggestions. However, resident developed diarrhoea as a result of codeine 
withdrawal and complained from insomnia; so both medicines were re-prescribed by the GP*.  
 
Amitriptyline  
(reduced, 
discontinued 
then re-
prescribed) 
 
 
Codeine 
(reduced then 
re-prescribed)  
Y N 
16 1 1 1 
Citalopram prescribed since admission into the residential care facility (approximately five 
years ago). Suggested trialling reduction from 20mg to 10mg as staff had reported that 
citalopram 20mg did not seem to lift resident’s moods significantly more. After three months 
of the reduction, resident communicated suicidal thoughts to staff. Therefore, GP* increased 
citalopram dose again.  
Citalopram 
(reduced then 
re-prescribed)  
Y N 
17 2 2 2 
Temazepam: Prescribed upon admission into the residential care facility (approximately two 
years ago). However, resident has been stable for the past year and expressed that he does not 
struggle to fall or stay asleep. In fact, the resident enjoys waking up at 4am on a daily basis. 
Therefore, suggested tapering temazepam dose from 20mg to 10mg with one 10mg tablet 
being prescribed ‘as required’ in case resident really requires it. The. GP agreed and tapering 
was well tolerated and resident did not require the extra temazepam tablet.  
 
Venlafaxine: Resident was prescribed a high dose of venlafaxine (375mg).  Has suffered from 
extensive mental health issues; including depression. However, resident reported good moods 
at time of the assessment and scored 4 on the geriatric depression scale test. Therefore, 
suggested reducing venlafaxine dose to 300mg (also a simpler medication pill regimen). GP 
agreed with this suggestion and resident tolerated this well.   
Temazepam  
(reduced)  
 
 
 
 
 
Venlafaxine  
(reduced)  
N Y 
18 0 0 0 
Resident suffers from severe pain and chronic depression. On several sedative medicines as 
well as moclobemide for depression. However, not feasible to discontinue medicines  
All medicines 
continued  N N 
19 1 1 1 
Resident prescribed escitalopram 10mg and admitted to not taking the medicine and throwing 
it out instead for the eight months prior to assessment date. Requested from the GP* to 
discontinue the medicine. At follow up, resident reported the same level of moods and quality 
of life.   
Escitalopram 
(discontinued) 
N Y 
20 0 0 0 
Prescribed escitalopram 20mg. However, behaviour is difficult to manage and has increased in 
difficulty, so not feasible to reduce or discontinue escitalopram  
Escitalopram 
(continued)  
N N 
21 0 0 0 Prescribed terazosin 2mg for severe incontinence. Not feasible to reduce or discontinue  
Terazosin 
(continued) N N 
22 0 0 0 
Citalopram: Prescribed for depression. Moods have been stable over the past year. However, 
moods have deteriorated close to the assessment date. Therefore, GP* charted citalopram 
instead of moclobemide  
All medicines 
continued   
N N 
23 1 1 1 
Temazepam: Prescribed 10mg. Initiated upon admission into the residential care facility. Has 
not had a previous trial of reducing or discontinuing temazepam. Therefore, suggested 
prescribing half a tablet (5mg) with the other half being prescribed ‘as required. GP* agreed 
Temazepam 
(reduced)  
N Y 
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and resident tolerated the reduction well  
24 1 1 1 
Amitriptyline: 10mg prescribed for an unclear indication. Resident prescribed several  other 
sedative medicines for pain control. Therefore, questioned the need for amitriptyline. Both 
resident and daughter voiced that amitriptyline is probably not needed. Therefore, suggested 
tapering then discontinuing amitriptyline. GP* agreed. However, resident complained of 
increased insomnia and GP* re-prescribed it  
Amitriptyline 
(reduced, 
discontinued, 
then re-
prescribed)  Y N 
      25 1 1 1 
Citalopram: Reduced citalopram from 20mg to 10mg over three months and eventually 
discontinued this medicine as the resident tolerated the reduction well. However, the patient's 
moods deteriorated and re-prescribing of citalopram was necessary.  
Citalopram 
(reduced, 
discontinued, 
then re-
prescribed)  Y N 
26 1 1 1 
Sertraline: Initiated upon admission into the residential care facility approximately 1 year and 
a half years prior to assessment date. Resident has settled into the residential care facility and 
moods stable. Suggested slow tapering and discontinuation. GP* agreed and resident tolerated 
this well.  
Sertraline 
(discontinued)  
N Y 
27 1 0 1 
Deprescribing zopiclone is not feasible as they had recently lost their spouse and had been 
unsettled.  
All medicines 
continued  N N 
28 1 1 1 
Terazosin: Resident recently had an in-dwelling catheter (IDWC) inserted, so deprescribed 
terazosin 
Terazosin 
(discontinued)  N Y 
29 1 0 1 
Escitalopram: Resident suffers from bipolar disorder. Prescribed multiple antidepressants. 
Resident had scored 3 on the geriatric depression scale (<5: not depressed) at the time of 
assessment. Therefore, suggested monotherapy antidepressant therapy to the GP* by reducing 
escitalopram.  However, resident suffered from an episode of bipolar low shortly afterwards, 
and it was not suitable to deprescribe escitalopram  
All medicines 
continued  
 
N N 
30 1 1 1 
Clonazepam: Prescribed 0.5mg BD* for an unclear indication. Resident reported increased 
sedation during the day. Therefore, recommended trialling a reduction of this medicine to help 
improve resident’s level of sedation. 
Clonazepam  
(reduced)  
N Y 
31 0 0 0 
All medicines prescribed are clinically appropriate and required medically. No deprescribing 
recommendations put forward.  
All medicines 
continued  
N N 
32 1 1 1 
Codeine: Prescribed 60mg BD*. Suggested reducing codeine dose to 30mg BD. GP  agreed. 
However, resident experienced increased pain from stoma and codeine was increased.  
Codeine 
(reduced, then 
increased)  Y N 
33 1 1 1 
Escitalopram: Resident prescribed 20mg of escitalopram with no clear indication. Resident 
scored 3 on geriatric depression scale suggesting no active depression and reports good 
moods. Suggested trialling the reduction of escitalopram. GP* agreed and resident tolerated 
this well.  
Escitalopram 
(reduced)  
 
N Y 
34 1 1 1 
Escitalopram: Indication unclear. Resident reports good moods and scored 2 on the geriatric 
depression scale. Discussed with resident and resident’s daughter the need to continue 
escitalopram and they both agreed to a trial of reduction. GP* agreed with the 
recommendation. Escitalopram was reduced over three months and eventually discontinued. 
Escitalopram 
(discontinued)  
N Y 
35 1 1 1 
Tramadol: On multiple sedatives, in addition to paracetamol and gabapentin. Reviewed the 
need for tramadol given the complex medicine regimen. Discussed this with the resident and 
resident’s family who agreed to reducing tramadol. GP* agreed. Resident tolerated this well 
and eventually tramadol was discontinued.  
Tramadol 
(discontinued)  
N Y 
36 0 0 0 
Unable to implement any deprescribing recommendations as resident passed away due to a 
myocardial infarction on 10/08/2016, before the date of the initial assessment  
All medicines 
continued  N N 
37 1 0 0 
Sertraline: Recommended slow tapering of sertraline as moods have been stable. However, 
moods deteriorated shortly after assessment and deprescribing was not feasible   
All medicines 
continued  
N N 
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38 1 1 1 
Citalopram: Prescribed for an unclear indication. Resident scored 2 on geriatric depression 
scale and reports good moods. Spoke to resident and son who agreed to a trial of 
deprescribing. GP* agreed. Resident tolerated reduction well and citalopram was discontinued.  
Citalopram 
(discontinued) 
N Y 
39 1 1 1 
Codeine: Prescribed high doses of codeine for shoulder/hip pain. Suggested to GP* to increase 
regular paracetamol use for more effective pain relief and gradually taper codeine use. 
Resident tolerated this well and no longer needed higher doses of codeine.  
Codeine 
(reduced) 
N Y 
40 1 1 1 
Alprazolam: Prescribed 500mcg of alprazolam TDS* for severe anxiety/post-traumatic stress 
disorder for over 15 years after the sudden loss of loved ones. Suggested to resident the 
gradual reduction of alprazolam. Resident and GP* agreed with this suggestion. Alprazolam 
250mcg TDS* was prescribed regularly along with 250mcg TDS* as required, in case the 
resident needed it during the first few weeks of reduction. Resident tolerated the reduction 
well and did not request alprazolam as required.   
Alprazolam 
(reduced)  
N Y 
41 1 1 1 
Ropinirole: Prescribed with no clear indication. Resident and GP* agreed to stop ropinirole. 
Patient tolerated this well.  
Ropinirole 
(discontinued)  N Y 
42 1 1 1 
Clonazepam: Resident prescribed 0.5mg three years ago after an outburst of aggression. 
Resident’s mood had settled and no further acts of aggression have occurred. Therefore, 
suggested discontinuing clonazepam. GP* agreed and resident tolerated this.  
Clonazepam 
(discontinued)  
N Y 
43 0 0 0 
Suffers from hallucinations and severe insomnia. Therefore, not feasible to deprescribe any 
target medicines (zopiclone, olanzapine)  
All medicines 
continued  N N 
44 1 0 1 
Quetiapine: Resident suffers from dementia. Quetiapine prescribed for no clear indication. 
Resident’s moods have been stable according to family members and staff and agree to 
trialling a reduction. Therefore suggested gradual tapering of quetiapine and discontinuation. 
However, GP* did not agree with this suggestion. No clear reason was given as to why GP* 
disagreed with this recommendation  
All medicines 
continued 
N N 
45 0 0 0 
Citalopram: Recently admitted into hospital for acopia before being transferred to the 
residential care facility, where he was prescribed citalopram. Therefore, was not suitable to 
deprescribe citalopram  
All medicines 
continued  
N N 
46 1 0 1 
Zopiclone: Prescribed 7.5mg for the past ten years. Resident reports that zopiclone doesn’t 
improve their sleep greatly. Therefore, suggested slowly tapering zopiclone to half a tablet 
regularly and half a tablet as required. However, GP did not agree. No clear reason was given 
as to why GP disagreed with this recommendation   
All medicines 
continued  
N N 
All 
residents  52   37  43   
 
  
GP: General practitioner; Y: Yes; N: No; BD: Twice daily; SR: Sustained release; mane: morning; TDS: Three times a day;  
Colour Meaning  
 
Deprescribed medicines were not represcribed 
 
Deprescribed but medicines were represcribed   
 
 
One or more medicines were successfully deprescribed 
(discontinued or reduced) 
 
GP trialled deprescribing; but medicines had to be 
represcribed  
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Deprescribing recommendations were not taken up by 
the GP, or the clinical situation of the resident changed; 
deeming them unsuitable to implement 
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Table 3: Outcome measures three months after deprescribing 
Outcome  Statistical test  Effect size P value  
Primary outcome 
DBI  WSR* Median: 0.09 p<0.001  
 
DBI prn  WSR Median: 0  0.41  
 
Secondary Outcomes 
UKU-SERS score:  
Psychiatric  
 
Neurological  
 
Autonomic  
 
Other 
WSR Median: 3.5  p <0.05  
Paired t-test  Mean: -1.83 
95% CI= -2.62;1.00  
p <0.001 
  
WSR Median: 1.5  p <0.001 
WSR Median: 0  0.009 
 
WSR  Median: 1 p<0.001 
 
UKU-SERS score:  
Adverse drug 
reactions  
 
 
Improbable 
 
Possible 
Probable  
Paired t-test  Mean: -2.82 
95% CI= -4; -1.64 
p<0.05  
 
 
 
Paired t-test  Mean: -1.22  
 
95% CI= -2.09; -0.26  
p=0.01 
 
 
WSR Median: 1  p<0.05 
WSR  Median: 1 p<0.05  
Cognitive 
Performance Score 2 
WSR  Median: 0  0.29  
Geriatric Depression 
Scale  
WSR  Median: 0.9  p<0.05  
*WSR: Wilson-Signed Rank Test  
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Table 4: Outcome measures six months after deprescribing 
 
 
 
*WSR=Wilcoxon signed ranked test 
 
 
 
 
 
 
 
 
 
Outcome  Statistical test  Effect size P value  
Primary outcome 
DBI  WSR* Median: 0.34  p<0.001  
 
DBI prn  WSR Median: 0  0.16   
 
Secondary Outcomes 
Regular Medicines  Paired t-test  Mean: -2.13  
95% CI = -4; -1.71  
P<0.05  
PRN Medicines   WSR  Median: -0.5 0.16 
Quality of Life  WSR  Median: 0  0.74 
Frailty Paired t-test  Mean: -1.35  
95% CI=-2.22: -0.48 
 
Number of falls  WSR  Median: 0  0.04  
UKU-SERS score:  
Psychiatric  
 
Neurological  
 
Autonomic  
 
Other 
WSR Median: -5.5 p <0.05  
Paired t-test  Mean: -2.24  
95% CI= -3.63; -1.12 
p <0.001 
  
WSR Median: -2 p <0.001 
WSR Median: -1 p <0.001  
 
WSR  Median: -1 p<0.001 
 
UKU-SERS score:  
Adverse drug 
reactions  
 
 
Improbable 
 
 
Possible 
Probable  
Paired t-test  Mean: -4.24 
95% CI= -5.66; -2.83 
p<0.05  
 
 
 
Paired t-test  Mean: -0.31 
95% CI=-2.05; -0.26 
p=0.52 
 
 
WSR Median: -3 p<0.001 
WSR  Median: -2 p<0.001  
Cognitive 
Performance Score 1  
WSR  Median: 0 0.9 
Cognitive 
Performance Score 2 
WSR  Median: 0  0.6  
Geriatric Depression 
Scale  
WSR  Median: -2 p<0.05  
Proportion of 
recommendations 
taken up by GPs 
Fisher’s exact test   p<0.05   
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